Recent advances towards the discovery of dopamine receptor ligands

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 5, 2006, Pages 587-630

  Zhang, Ao ^a,b   Kan, Ying ^c   Li, Fuying ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b MCLEAN HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

Atypical antypsychotic; Brain disorder; CNS; Dopamine; Dopamine agonist; Dopamine antagonist; Dopamine receptor; Parkinson's disease; Schizophrenia; Serotonin

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; ARIPIPRAZOLE; BROMOCRIPTINE; CABERGOLINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; OLANZAPINE; PERGOLIDE; PERPHENAZINE; PRAMIPEXOLE; QUETIAPINE; RECEPTOR SUBTYPE; RISPERIDONE; ROPINIROLE; SPIPERONE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG;

BODY WEIGHT DISORDER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG STRUCTURE; DYSKINESIA; DYSTONIA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROANATOMY; NONHUMAN; PARKINSON DISEASE; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SUBSTANTIA NIGRA; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 33646591225     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.5.587     Document Type: Review

References (103)

1. SEEMAN P: Brain dopamine receptors. Pharmacol. Rev. (1980) 32:229-313.
2. TAMMINGA CA: Partial dopamine agonists in the treatment of psychosis. J. Neural Transm. (2002) 109:411-420.
3. ELSWORTH JD, ROTH RH: Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp. Neurol. (1997) 144:4-9.
4. MAHARAJAN P, MAHARAJAN V, RAVAGNAN G, PAINO G: The weaver mutant mouse: a model to study the ontogeny of dopamine transmission systems and their role in drug addiction. Prog. Neurobiol. (2001) 64:269-276.
5. JABER M: Dopamine control of neuroendocrine function: novel findings based on studies of transgenic animals. Ann. Endocrinol. (1998) 58:427-435.
6. KEBABIAN JW, CALNE DB: Multiple receptors for dopamine. Nature (1979) 277:93-96.
7. HESS EJ, BRACHA HS, KLEINMAN JE et al.: Dopamine receptor subtype imbalance in schizophrenia. Life Sci. (1987) 40:1487-97.
8. CIVELLI O, BUNZOW JR, GRANDY DK: Molecular diversity of the dopamine receptors. Ann. Rev. Pharmacol. Toxicol. (1992) 32:281-307
9. FREMEAU RT, DUNCAN GE, FORNARETTO MG et al.: Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc. Natl. Acad. Sci. USA (1991) 88:3772-3776.
10. SPANO PF, GOVONI S, TRABUCCHI M: Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv. Biochem. Psychopharmacol. (1978) 19:155-156.
11. SEEMAN P: Dopamine receptors: clinical correlates. In: Psychopharmacology: the Forth Generation of Progress. Borroni E, Kupfer DJ, (Eds), Raven Press Ltd, New York (1995):295-230.
12. BUCKLAND PR, O'DONOVAN MC, MCGUFFIN P: Both splicing variants of the dopamine D2 receptor mRNA are up-regulated by antipsychotic drugs. Neurosci. Lett. (1993) 150:25-28.
13. long dopamine receptors expressed in recombinant cells. Br. J. Pharmacol. (1996) 118:1544-1550.
14. BRESSAN RA, CRIPPA JA: The role of dopamine in reward and pleasure behavior - review of data from preclinical research. Acta Psychiatr. Scand. (2005) 111(Suppl.427):2-14.
15. EBADI M, CHAGKUTIP J: MPTP disrupts dopamine receptors and dopamine transporters. Parkinson's disease (2005) 433-441.
16. RAO G: Does this patient have Parkinson's disease? J. Am. Med. Assoc. (2003) 289:347-353.
17. AGID Y: Biochemistry of Parkinson's disease 28 years later: a critical review. Mov. Disord. (1989) 4:S126-S144.
18. RUBERG M: Dopamine denervation, age of onset, and Parkinson's disease. Neurology (1995) 45:392-393.
19. BIRKMAYER W, HORNYKIEWICZ O: The effect of L-3,4-dihydroxyphenylalanine (L-DOPA) on akinesia in Parkinsonism. Parkinsonism Relat. Disord. (1961) 4:59-60.
20. WOLTERS EC: Preclinical (premotor) Parkinson's disease. J. Neurol. (2000) 247(Suppl.2):II103-II109.
21. AUBERT I: Increased D1 dopamine receptor signalling in levodopa-induced dyskinesia. Ann. Neurol. (2005) 57:17-26.
22. JENNER P: Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr. Opin. Neurol. (2003) 16:S3-S7.
23. COTZIAS GC: Similarities between neurologic effect of L-dopa and of apomorphine. New Engl. J. Med. (1970) 282:31-35.
24. RINNE UK: Early dopamine agonist treatment in Parkinson's disease. In: Parkinson's disease: the Role of Dopamine Agonists. Lieberman A, Lataste X (Eds), The Partheon Publishing Group, UK (1989):29-35.
25. MONTASTRUC JL: A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five-year follow up. J. Neurol. Neurosurg. Psychiatry (1994) 57:1034-1038.
26. RINNE UK: Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurol. Scand. Suppl. (1983) 95:19-26.
27. FAHN S, CALNE DB: Consideration in the management of parkinsonism. Neurology (1978) 28:5-7.
28. CLARKE CE: Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol. (2004) 3:466-474.
29. MERCURI NB, BERNARDI G: The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol. Sci. (2005) 26:341-344.
30. COMINGS DE, BLUM K: Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog. Brain Res. (2000) 126:325-341.
31. WILLNER P: The dopamine hypothesis of schizophrenia: current status, future prospects. Int. Clin. Psychopharmacol. (1997) 12:297-308.
32. MOORE H, WEST AR, GRACE AA: The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol. Psychiat. (1999) 46:40-55.
33. ABI-DARGHAM A: Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. (2004) 7(Suppl.1):S1-S5.
34. 11C]Propyl-norapomorphine: a positron-labeled dapamine agonist for PET imaging of D2 receptors. Nucl. Med. Biol. (2000) 27:533-539.
35. 11C]-propyl-norapomorphine in vivo binding in nonhuman primates. J. Nucl. Med. (2004) 45:338-346.
36. 11C]raclopride. Synapse (2004) 52:188-208.
37. LARUELLE M, ABI-DARGHAM A: Dopamine imbalances in the schizophrenic brain: imaging studies. Neurol. Dis. Ther. (2003) 56:593-642.
38. VOLKOW ND: Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav. Pharmacol. (2002) 13:355-366.
39. INOUE A, NAKATA Y: Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn. J. Pharmacol. (2001) 86:376-380.
40. 2+ connection in dopamine signaling. Trends Pharmacol. Sci. (2003) 24:486-492.
41. GOLDMAN-RAKIC PS: The cortical dopamine system: role in memory and cognition. Adv. Pharmacol. (1998) 42:707-711.
42. SCHULTZ W: Getting formal with dopamine and reward. Neuron (2002) 36:241-263.
43. YELNIK J: Functional anatomy of the basal ganglia. Mov. Disord. (2002) 17(Suppl.3):S15-S21.
44. SWERDLOW NR, KOOB GF: Dopamine, schizophrenia, mania, and depression: toward a unified hypothesis of cortico-striato-palido-thalamic function. Behav. Brain Sci. (1987) 10:197-245.
45. SOLANTO MV: Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav. Brain Res. (2002) 130:65-71.
46. MULLER-VAHL KR: The treatment of Tourette's syndrome: current opinions. Expert Opin. Pharmacother. (2002) 3:899-914.
47. CHENG C, JIANG F: Recent advances in structure activity relationship of dopamine D2-like receptor ligands. Zhongguo Yaowu Huaxue Zazhi (2003) 13:179-186.
48. BOGESO KP, BANG-ANDERSEN B: Dopamine and serotonin receptor and transporter ligands. In: Textbook of Drug Design and Discovery. Krogsgaard-Larsen P, Liljefors T, Madsen U (Eds), Taylor & Francis Ltd, London (2002):299-327.
49. PERTZ H, EICH E: Ergot alkaloids and their derivatives as ligands for serotoninergic, dopaminergic, and adrenergic receptors. Medicinal Aromatic Plants Industrial Profiles (1999) 6(Ergot):411-440.
50. SOSKIC V, JOKSIMOVIC J: Bioisosteric approach in the design of new dopaminergic/serotonergic ligands. Curr. Med. Chem. (1998) 5:493-512.
51. KEBABIAN JW, TARAZI FI, KULA NS, BALDFSSARINI RJ: Compounds selective for dopamine receptor subtypes. Drug Discov. Today (1997) 2:333-340.
52. BALDESSARINI RJ: Dopamine receptors and clinical medicine. Dopamine Recept. (1997):457-498.
53. MAILMAN RB, NICHOLS DE, TROPSHA A: Molecular drug design and dopamine receptors. Dopamine Recept. (1997):105-133.
54. TENBRINK RE, HUFF RM: Recent advances in dopamine D3 and D4 receptor ligands and pharmacology. Ann. Rep. Med. Chem. (1994) 29:43-52.
55. SYVALAHTI EK: Dopamine receptors and psychiatric drug treatment. Ann. Clin. Res. (1988) 20:340-347.
56. WIKSTROEM H: Centrally acting dopamine D2 receptor ligands: agonists. Prog. Med. Chem. (1992) 29:185-216.
57. HACKLING AE, STARK H: Dopamine D3 receptor ligands with antagonist properties. Chembiochem (2002) 3:946-961.
58. WILSON JM, SANYAL S, VAN TOL HH: Dopamine D2 and D4 receptor ligands: relation to antipsychotic action. Eur. J. Pharmacol. (1998) 351:273-86.
59. IMHOF R, GODEL T, BURKARD WP, KELLER HH, DA PRADA M, SCHERSCHLICHT R: New insight into structural and stereochemical requirements for selective, high affinity ligands at the dopamine D2 receptor. Neurochem. Int. (1992) 20(Suppl.):75S-80S.
60. HOGBERG T: The development of dopamine D2 receptor selective antagonists. Drug Des. Discov. (1993) 9:333-350.
61. GRAU D, PHIL P, SERBEDZIJA G: Innovative strategies for drug repurposing. Drug Discov. Dev. (2005) 8:56-61.
62. KELLEHER JP, CENTORRINO F, ALBERT MJ, BALDESSARRINI RJ: Advances in atypical antipsychotics for the treatment of schizophrenia. CNS Drugs (2002) 16:249-261.
63. ROWLEY M, BRISTOW LJ, HUTSON PH: Current and novel approaches to the drug treatment of schizophrenia. J. Med. Chem. (2001) 44:477-501.
64. ASPRONI B, PAU A, BITTI M et al.: Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D2, serotonin, and GABAA receptors. J. Med. Chem. (2002) 45:4655-4668.
65. WU WL, BURNETT DA, SPRING R et al.: Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. J. Med. Chem. (2005) 48:680-693.
66. MACDONALD GJ, BRANCH CL, HADLEY MS et al.: Design and synthesis of trans-3-(2-(4-((3-(3-(5-mMethyl-1,2,4-oxadiazolyl)) -phenyl)carboxamido)cyclohex yl)ethyl)-7-methylsulfonyl- 2,3,4,5-tetrahyd ro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist. J. Med. Chem. (2003) 46:4952-4964.
67. AUDOUZE K, NIELSEN EQ, PETERS D et al.: New series of morpholine and 1,4-oxazepane derivatives as dopamine D4 receptor ligands: synthesis and 3D-QSAR model. J. Med. Chem. (2004) 47:3089-3104.
68. CAMPIANI G, BUTINI S, FATTORUSSO C et al.: Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J. Med. Chem. (2004) 47:143-157.
69. CAMPIANI E, BUTINI S, FATTORUSSO C et al.: Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. J. Med. Chem. (2005) 48:1705-1708.
70. FERNANDEZ J, ALONSO JM, ANDRES JI et al.: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J. Med. Chem. (2005) 48:1709-1712.
71. TRABANCO AA, ALONSO JM, ANDRES JI et al.: Synthesis of 2-N,N-(dimethylamino)-2,3,3a, 12b-tetrahydrodibenzo[b,f]furo[2,3-d]oxep in derivatives as potential anxiolytic agents. Chem. Pharm. Bull. (2004) 52:262-265.
72. 2A/2C receptor antagonists. Bioorg. Med. Chem. Lett. (2004) 14:2765-2771.
73. TRENTON AJ, CURRIER GW, ZWEMER FL: Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs (2003) 17:307-324.
74. ALLISON DB, MENTORE JL, HEO M et al.: Antipsychotic-induced weight gain: a comprehensive reseach synthesis. Am. J. Psychiatry (1999) 156:1686-1696.
75. WETTERLING T: Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. (2001) 24:59-73.
76. 1 histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 28:519-526.
77. ORTHEN-GAMBILL N: Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats. Pharmacol. Biochem. Behav. (1988) 31:81-86.
78. WEIDEN P, AQUILA R, STANDARD J: Atypicalantipsychotic drugs and long-term outcome in schizophrenia. J. Clin. Psychiatry (1996) 57(Suppl.11):53-60.
79. WARAWA EJ, MIGLER BM, OHNMACHT CJ et al.: Behavioral approach to nondyskinetic dopamine antagonists: identification of Seroquel. J. Med. Chem. (2001) 44:372-389.
80. SOLOMON Y, LANDOS C, RODBELL M: A highly selective adenylyl cyclase assay. Anal. Biochem. (1974) 58:541-548.
81. WEISS S, SEBBEN M, BOCKAERT JJ: Corticotropin-peptide regulation of intracellular cyclic AMP production in cortical neurons in primary culture. J. Neurochem. (1985) 45:869-874.
82. MOLEWIJK HE, VAN DER POEL AM, MOS J et al.: Conditioned ultrasonic vocalizations in adult male rats as a paradigm for screening anti-panic drugs. Psychopharmacology (1995) 117:32-40.
83. UNGERSTEDT U: 6-OH-DA induced degeneration of central monoamine neurons. Eur. J. Pharnacol. (1968) 5:107-110.
84. NOMOTO M, JENNER P, MARSDEN CD: The dopamine agonist D2 agonist LY 141865 but not the D1 agonist SKF 38393, reverses Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common Marmoset. Neurosci. Lett. (1985) 57:37-41.
85. GAZI L, BOBIRNAC I, DANZEISEN M et al.: Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4 receptors expressed in CHO cells. Br. J. Pharmacol. (1999) 128:613-628.
86. ANNON JG, PEASE JP, HAMER RL, ILHAN M, BHATNAGAR RK, LONG JP: Resorcinol congeners of dopamine derived from benzocycloheptene and indan. J. Med. Chem. (1984) 27:186-189.
87. CANNON JG, DUSHIN RG, LONG JP et al.: Synthesis and dopaminergic activity of (R)- and (S)-4-hydroxy-2-(di-n-propylamino)indan. J. Med. Chem. (1985) 28:515-518.
88. CANNON JG, FURLANO DC, DUSHIN RG et al.: Assessment of a potential dopamenergic prodrug moiety in several ring systems. J. Med. Chem. (1986) 29:2016-2020.
89. HACKSELL U, ARVIDSSON LE, SVENSSON U et al.: Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity. J. Med. Chem. (1981) 24:429-34.
90. MA SX, LONG JP, FLYMNN JR, LEONARD PA, CANNON JG: Dopaminergic structure-activity relationships of 2-aminoindans and cardiovascular action and dopaminergic activity of 4-hydroxy, 5-methyl, 2-di-n-propylaminoindan (RD-211). J. Pharmacol. Exp. Ther. (1991) 256:751-756.
91. NICHOLS DE, BREWSTER WK, JOHNSON MP, OBERLENDER R, RIGGS RM: Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). J. Med. Chem. (1990) 33:703-710.
92. 3H]U-86170, a dopamine receptor agonist. Eur. J. Pharmacol. (1991) 202:289-291.
93. CHIO CL, HESS GF, GRAHAM RS, HUFF RM: A second molecular form of D2 dopamine receptor in rat and bovine caudate nucleus. Nature (1990) 343:266-268.
94. CHIO CL, LAJINESS ME, HUFF RM: Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol. (1994) 45:51-60.
95. BPGESO KP, ARNT J, FREDERIKSEN K, HANSEN HO, HYTTEL J, PEDERSEN H: Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity. J. Med. Chem. (1995) 38:4380-4392.
96. 3H] quinpirole. Eur. J. Pharmacol. (1991) 203:105-109.
97. 3H]spiroperidol. Brain Res. (1977) 136:578-584.
98. BLANCHET PJ, KONITSIOTIS S, HYLAND K et al.: Chronic exposure to MPTP as a primate model of progressive Parkinsonism: a pilot study with a free radical scavenger. Exp. Neurol. (1998) 153:215-222.
99. 3H]NGD94-1. J. Pharmacol Exp. Ther. (1997) 282:1020-1027.
100. GLASE SA, AKUNNE H, GEORGIC L et al.: Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists. J. Med. Chem. (1997) 40:1771-1772.
101. KAROLEWICZ B, ANTKIEWICZ-MICHALUK L, MICHALUK J, VETULANI J: Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain. Eur. J. Pharmacol. (1996) 267:181-186.
102. 1A receptors. Eur. J. Pharmacol. (1996) 307:107-111.
103. DE VRY J, BENZ U, SCHREIBER R, TRABER J: Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur. J. Pharmacol. (1993) 249:331-339.